YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
Takeda T, Yamamoto H, Suzawa K, Tomida S, Miyauchi S, Araki K, Nakata K, Miura A, Namba K, Shien K, Soh J, Shien T, Kitamura Y, Sendo T, Toyooka S.
Takeda T, et al. Among authors: soh j.
Cancer Sci. 2020 Mar;111(3):849-856. doi: 10.1111/cas.14289. Epub 2020 Jan 16.
Cancer Sci. 2020.
PMID: 31856375
Free PMC article.